Latest Tax Incentives News

Stakk Ltd (ASX: SKK) has delivered a striking 272% jump in gross receipts to $5.36 million in Q3 FY26, reversing prior cash outflows with a positive net cash flow of $2.25 million and closing the quarter with $17.34 million in cash.

Adslot Ltd achieved positive net operating cash flow in Q3 FY26 while trimming its workforce by nearly a third to sharpen focus on its Symphony and Webfirm units. The company is navigating declining marketplace revenues and preparing for a key contract renewal with Group M.

Wide Open Agriculture appoints Craig Swan as CEO and pivots to a contract manufacturing model to improve economics and scale lupin protein production, while receiving a A$1.69 million R&D tax rebate.

Radiopharm Theranostics (ASX: RAD) has completed enrolment in its Phase 2b RAD 101 brain metastases imaging trial with interim data showing 90% concordance with MRI, while progressing early-stage trials of therapeutic candidates RAD 202, RV-01, and RAD 402. The company reported a $19.2 million cash balance at quarter end, down from $34.5 million, with a net operating cash outflow of $14.9 million driven by milestone-related R&D and staff costs.

Bubalus Resources reports encouraging gold intercepts from maiden Avon Plains drilling while streamlining its portfolio to prioritise Victorian assets and critical minerals projects. The company maintains a solid $3 million cash buffer amid cost cuts and plans multiple exploration campaigns in the coming quarters.

Decidr AI Industries Ltd (ASX: DAI) reported a doubling of its annualised revenue run rate to A$8.06 million as of March 2026, alongside the launch of its Decidr Agentic Graph platform and significant expansion of its partner ecosystem.

Advanced Braking Technology Ltd (ASX: ABV) reported a 28% jump in product sales revenue to $6 million for Q3 FY26, driven by strong aftermarket sales and international market traction. The company also advanced certification of its autonomous BRAKEiQ system, targeting FY27 adoption.

Energy Action Limited posted a milestone quarter ending March 2026, delivering positive operating cash flow for the first time in FY26 alongside strong revenue gains and a notable $0.5 million debt repayment. Governance changes add a layer of uncertainty ahead of a scheduled general meeting.

Orthocell’s Q1 FY26 revenue hits $3.2 million, buoyed by growing US sales of its Remplir nerve repair device and a robust $48 million cash position supporting global expansion.

Entropy Neurodynamics has dosed its third patient with TRP-8803 in a Binge Eating Disorder trial, achieving a full and controlled psychedelic response that underscores the drug’s potential for precise therapeutic delivery.

EMVision Medical Devices has ramped up recruitment in its pivotal FDA trial across eight hospitals and is nearing results from multiple pre-hospital studies, all while bolstering its cash position with a $3.8 million R&D tax refund and $6.6 million in grant funding.

Wide Open Agriculture Ltd (ASX: WOA) has received a A$1,686,579 R&D tax rebate for the 2024-25 financial year, reflecting its significant innovation efforts in lupin protein development across Australia and Germany. The rebate will support the company’s commercialisation and growth initiatives.